Venture capital firms have invested over USD1.7 billion in generative AI solutions over the last three years, with AI-enabled drug discovery and AI software coding receiving the most funding.
Early foundation models like ChatGPT focus on the ability of generative AI to augment creative work, but by 2025, we expect more than 30% — up from zero today — of new drugs and materials to be systematically discovered using generative AI techniques. And that is just one of numerous industry use cases.